Should I buy Glaukos Corp. (GKOS) stock or is it too late?

Glaukos Corp. · Health Care · price $182
Logo Glaukos Corp.See the full Glaukos Corp. (GKOS) profile
⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: HC Wainwright & Co.61% of its targets hit on this sector (321 calls tested). It aims for $195 (+7.2 %), call made on July 31, 2026, maturing on July 31, 2027 (28 d ago).

The 2 reliable analysts $184+0.9 %
The 8 other firms $193+5.8 %
How to read it: the 2 reliable firms are not filtered by optimism — 1 aim above the price, 1 below, hence their $184 median. “The 8 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on Glaukos Corp.

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.
Firm% rightGain vs sectorCallsAims for
Stephens & Co.86 %+89.0 %7$145 -20%
Piper Sandler75 %+56.9 %8$195 +7%
Needham77 %+45.2 %13$201 +10%
Truist Securities50 %+24.9 %12$215 +18%
JP Morgan56 %+23.7 %9$140 -23%
Stifel45 %+20.4 %11$190 +4%
BTIG33 %+2.3 %9$202 +11%
Citigroup50 %-10.5 %8$188 +3%
In short — Should you invest in Glaukos Corp.? Is it too late, still worth it? Analysts are overwhelmingly positive (90% buy, median target $193, i.e. +6%). But it pays virtually no dividend. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

  • 90% of analysts rate it a buy (Buy consensus, 10 ratings) — a sign of market conviction.

⚠️ Reasons to hesitate

  • Even the most reliable firm on GKOS, Stephens & Co. (86% hit rate, 7 scored calls), only targets $145 (call made on January 2, 2026, maturing on January 2, 2027) (-20%) in its most recent call. The stock may already have run past its target.
  • The consensus is not unanimous: of 10 ratings, 1 is neutral.
  • Limited upside: the median target is only +6% from the current price.
  • A 12-month target is not a guaranteed path: the price can fall in the meantime.
  • No dividend: your return depends only on price appreciation.

The analyst consensus on GKOS

Median target $193 (+6%) · 10 ratings · Buy consensus

Strong Buy00%
Buy990%
Hold110%
Sell00%
Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in Glaukos Corp. now?

We won't decide for you. The facts: 90% of analysts rate it a buy, median target $193 (+6%), and Stephens & Co. (most reliable on GKOS, 86%) targets $145. Weigh that against valuation. This is not personalized advice.

Is it too late to invest in Glaukos Corp.?

Not according to analysts: the median target ($193) is still +6% above the current price ($182) (most reliable on GKOS: Stephens & Co., 86%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is Glaukos Corp. still worth investing in?

It depends on the gap between the price ($182) and its estimated value: analysts target $193 on median (+6%), with 90% buys (most reliable on GKOS: Stephens & Co., 86%). Cross-check with their real reliability on GKOS and the cautions above. Information, not advice.

What's the main risk in buying GKOS?

Even the most reliable firm on GKOS, Stephens & Co. (86% hit rate, 7 scored calls), only targets $145 (call made on January 2, 2026, maturing on January 2, 2027) (-20%) in its most recent call. The stock may already have run past its target.

→ Go deeper: the full Glaukos Corp. profile (consensus, analyst reliability, price target, performance).

JPI AI Analyst AI assistant · JPI Invest
Answers based on the tool’s data · not financial advice · full version (free)